Analyzing Economic Effect on MRNA Vaccine Inventory Management with Redistribution Policy

Overview

Journal Sci Rep

Specialty Science

Date 2024 Sep 3

PMID 39227428

Authors

Hyungju Kim

Hyungjoo Cha

Taesu Cheong

Affiliations

Soon will be listed here.

Abstract

This study focused on the challenges posed by the fluctuating demand for COVID-19 vaccines, considering factors such as side effects, religious objections, and absenteeism, which result in the accumulation of excess vaccines. Recognizing the resulting social, economic, and environmental issues, this study investigated the application of a lateral transshipment policy for the management of the inventory of short-term vaccines, considering related unpredictabilities. A discrete event simulation built on foundational principles derived from a mixed-integer linear programming model was employed to explore the dynamics of mRNA-based vaccine distribution among two hospitals based on lateral transshipment and reordering policies. Through the simulation of various scenarios over periods of 1-30 days, transshipment based on the availability policy is employed to determine the quantity of vaccines to be transshipped, constrained to vial amounts, and the (s, S) inventory system for reordering. The results of this study underscore the efficacy of lateral transshipment, particularly in situations where demand discrepancies exist between hospitals, thereby revealing its superiority over non-transshipment strategies within 7 days.

Citing Articles

Advantages of Broad-Spectrum Influenza mRNA Vaccines and Their Impact on Pulmonary Influenza.

Cheng Z, Ma J, Zhao C Vaccines (Basel). 2025; 12(12.

PMID: 39772044 PMC: 11680418. DOI: 10.3390/vaccines12121382.

References

Yan Y, Pang Y, Lyu Z, Wang R, Wu X, You C . The COVID-19 Vaccines: Recent Development, Challenges and Prospects. Vaccines (Basel). 2021; 9(4). PMC: 8067284. DOI: 10.3390/vaccines9040349. View

Schoenmaker L, Witzigmann D, Kulkarni J, Verbeke R, Kersten G, Jiskoot W . mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm. 2021; 601:120586. PMC: 8032477. DOI: 10.1016/j.ijpharm.2021.120586. View

Holm M, Poland G . Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy. Vaccine. 2020; 39(3):457-459. PMC: 7723768. DOI: 10.1016/j.vaccine.2020.12.017. View

Uddin M, Roni M . Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines. Vaccines (Basel). 2021; 9(9). PMC: 8473088. DOI: 10.3390/vaccines9091033. View

Rosenberg E, Dorabawila V, Easton D, Bauer U, Kumar J, Hoen R . Covid-19 Vaccine Effectiveness in New York State. N Engl J Med. 2021; 386(2):116-127. PMC: 8693697. DOI: 10.1056/NEJMoa2116063. View

Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C . A global database of COVID-19 vaccinations. Nat Hum Behav. 2021; 5(7):947-953. DOI: 10.1038/s41562-021-01122-8. View

Pierri F, Perry B, DeVerna M, Yang K, Flammini A, Menczer F . Online misinformation is linked to early COVID-19 vaccination hesitancy and refusal. Sci Rep. 2022; 12(1):5966. PMC: 9043199. DOI: 10.1038/s41598-022-10070-w. View

Lee S, Sun J, Jang S, Connelly S . Misinformation of COVID-19 vaccines and vaccine hesitancy. Sci Rep. 2022; 12(1):13681. PMC: 9366757. DOI: 10.1038/s41598-022-17430-6. View

Rudloff J, Hutmacher F, Appel M . Post-truth epistemic beliefs rooted in the Dark Factor of Personality are associated with higher COVID-19 vaccination refusal. Sci Rep. 2023; 13(1):4254. PMC: 10013296. DOI: 10.1038/s41598-023-31079-9. View

10.

Musamih A, Salah K, Jayaraman R, Yaqoob I, Al-Hammadi Y, Antony J . Blockchain-based solution for COVID-19 vaccine waste reduction. J Clean Prod. 2022; 372:133619. PMC: 9389451. DOI: 10.1016/j.jclepro.2022.133619. View

11.

Ganesan S, Mohammad Baynouna Al Ketbi L, Al Kaabi N, Al Mansoori M, Al Maskari N, Al Shamsi M . Vaccine Side Effects Following COVID-19 Vaccination Among the Residents of the UAE-An Observational Study. Front Public Health. 2022; 10:876336. PMC: 9120526. DOI: 10.3389/fpubh.2022.876336. View

12.

Fahrni M, Ismail I, Refi D, Almeman A, Yaakob N, Saman K . Management of COVID-19 vaccines cold chain logistics: a scoping review. J Pharm Policy Pract. 2022; 15(1):16. PMC: 8889047. DOI: 10.1186/s40545-022-00411-5. View

13.

Rastegar M, Tavana M, Meraj A, Mina H . An inventory-location optimization model for equitable influenza vaccine distribution in developing countries during the COVID-19 pandemic. Vaccine. 2020; 39(3):495-504. PMC: 7833064. DOI: 10.1016/j.vaccine.2020.12.022. View

14.

Thul L, Powell W . Stochastic optimization for vaccine and testing kit allocation for the COVID-19 pandemic. Eur J Oper Res. 2021; 304(1):325-338. PMC: 8580866. DOI: 10.1016/j.ejor.2021.11.007. View

15.

Wen Z, Yue T, Chen W, Jiang G, Hu B . Optimizing COVID-19 vaccine allocation considering the target population. Front Public Health. 2023; 10:1015133. PMC: 9853449. DOI: 10.3389/fpubh.2022.1015133. View

16.

Kim Y, Choi Y, Min Y . A model of COVID-19 pandemic with vaccines and mutant viruses. PLoS One. 2022; 17(10):e0275851. PMC: 9591069. DOI: 10.1371/journal.pone.0275851. View

17.

Caglayan C, Thornhill J, Stewart M, Lambrou A, Richardson D, Rainwater-Lovett K . Staffing and Capacity Planning for SARS-CoV-2 Monoclonal Antibody Infusion Facilities: A Performance Estimation Calculator Based on Discrete-Event Simulations. Front Public Health. 2022; 9:770039. PMC: 8831825. DOI: 10.3389/fpubh.2021.770039. View

18.

Harris C, Millman K, van der Walt S, Gommers R, Virtanen P, Cournapeau D . Array programming with NumPy. Nature. 2020; 585(7825):357-362. PMC: 7759461. DOI: 10.1038/s41586-020-2649-2. View